

REVENIO

Revenio Group Corporation: Financial Statements

January 1 – December 31, 2025

Revenio Group Corporation: Financial Statements

Release January 1 – December 31, 2025

Continued sales growth and exceptionally strong cash flow

The figures in parentheses refer to the corresponding period in the previous year unless otherwise stated.

October–December 2025

- Net sales totaled EUR 31.2 (30.5) million, up by 2.2%
- The currency-adjusted net sales increased 8.6%
- Operating profit was EUR 6.7 (9.1) million, or 21.4% of net sales, down by 26.9%
- The adjusted operating profit was EUR 7.2 (9.3) million, or 22.9% of net sales, down by 22.7%
- EBITDA was EUR 7.8 (10.3) million, or 24.9% of net sales, down by 24.2%
- Cash flow from operating activities totaled EUR 15.9 (9.8) million
- Earnings per share came to EUR 0.208 (0.247)

January–December 2025


- Net sales totaled EUR 109.7 (103.5) million, up by 6.0%
- The currency-adjusted net sales increased 9.1%
- Operating profit was EUR 25.4 (25.0) million, or 23.2% of net sales, up by 1.4%
- The adjusted operating profit was EUR 26.5 (26.0) million, or 24.2% of net sales, up by 2.3%
- EBITDA was EUR 29.9 (30.2) million, or 27.3% of net sales, down by 1.1%
- Cash flow from operating activities totaled EUR 30.2 (23.9) million
- Earnings per share came to EUR 0.655 (0.695)
- The Annual General Meeting was held on April 10, 2025. The dividend was confirmed as EUR 0.40.
- The Board of Directors will propose to the Annual General Meeting of April 15, 2026, that the General Meeting authorizes the Board to decide, at its discretion, on the payment of a possible dividend of up to EUR 0.44 per share by December 31, 2026.

NET SALES Q4/2025	OPERATING PROFIT Q4/2025	EBITDA Q4/2025
31.2 (30.5) M€	6.7 (9.1) M€	7.8 (10.3) M€
EPS Q4/2025	CURRENCY-ADJUSTED NET SALES Q4/2025	+8.6%
		0.208 (0.247) €


Key consolidated figures

MEUR	10-12/2025	10-12/2024	Change-%	1-12/2025	1-12/2024	Change-%
Net sales	31.2	30.5	2.2	109.7	103.5	6.0
Gross margin	21.1	21.7	-2.7	77.8	72.9	6.7
Gross margin - %	67.6	71.0	-4.8	70.9	70.5	0.7
EBITDA	7.8	10.3	-24.2	29.9	30.2	-1.1
EBITDA-%	24.9	33.6	-25.8	27.3	29.2	-6.7
Operating profit, EBIT	6.7	9.1	-26.9	25.4	25.0	1.4
Operating profit-%, EBIT	21.4	29.9	-28.5	23.2	24.2	-4.3
Adjusted Operating profit, EBIT	7.2	9.3	-22.7	26.5	26.0	2.3
Adjusted Operating profit-%, EBIT	22.9	30.3	-24.4	24.2	25.1	-3.5
Return on investment-%, ROI	6.6	8.4	-21.4	20.8	22.1	-5.9
Return on equity-%, ROE	5.0	6.3	-20.6	15.7	17.8	-11.8
Earnings per share	0.208	0.247		0.655	0.695	
MEUR	31.12.2025	31.12.2024	Change, %-point			
Equity ratio-%	76.1	76.2	-0.1			
Gearing-%	-13.3	-7.3	-6.0			


Net sales, M€




Geographic distribution of net sales 2025, %




Operating profit, EBIT, M€



EBITDA, M€



Cash flow from operations, M€



Financial guidance for 2026

Revenio Group's exchange rate-adjusted net sales are estimated to grow 8-15 percent from the previous year and profitability, excluding non-recurring items, is estimated to remain at a good level.

Comments from CEO Jouni Toijala

I am pleased with our performance in 2025. In our view, we have been able to increase our market share in our key product categories. Sales in US grew strongly in the fourth quarter and we reached an all-time sales record in the US in December. In addition, we achieved an all-time high cash flow during the fourth quarter. Our currency-adjusted net sales for the fourth quarter increased by 8.6 %. Our reported net sales increased by 2.2% in the fourth quarter to EUR 31.2 (30.5) million.

Sales in the fourth quarter were primarily driven by our stable, recurring order flow, with no major one-off orders towards year-end. Our sales pipeline includes several interesting opportunities that are larger than our typical orders; discussions are ongoing, but their realization and timing are inherently challenging to predict.

Exchange rates had a lowering impact on net sales and thereby profitability compared to the previous year. In the EMEA region, good sales growth continued in the fourth quarter. Sales in the APAC region declined in the final quarter of the year compared to the strong comparison period. Sales were particularly weighed down by the strengthening of the euro against the local currencies of the region's key markets. Thanks to the strong start to the year, however, APAC sales still achieved solid growth for the full year. We invoice our products in euros in all markets, with the exception of the United States. Dollar-denominated sales developed positively during the review period, although the headwinds of the USD/EUR exchange rate slowed down growth in euros.

In the fourth quarter, we began to see the impact of tariffs in the United States. The impact of delayed price increases temporarily weakened fourth-quarter gross margin and profitability. The impact of the unrealized price increases on margin and profitability was approximately 2 percentage points. The price increases will be fully implemented in early 2026.

Continuous business, such as sales of software licenses, service contracts, and probes, already accounted for nearly one-third of our net sales during the year, and we expect its share to grow in the future.

Net sales developed favorably in January–December – reported net sales amounted to EUR 109.7 (103.5) million, an increase of 6.0%. The development of sales adjusted for exchange rate effects in 2025 was at a good level, growing by 9.1% year-on-year.

Best-in-industry profitability

Our profitability was at a good level, the operating profit amounting to 21.4% of net sales in the fourth quarter, despite the momentary decrease in operating profit. The operating profit was weighed down by non-recurring costs of EUR 0.5 million, such as costs related to employment contracts terminated as a result of change negotiations and other costs related to non-recurring projects. EBITDA adjusted for the non-recurring expenses amounted to EUR 7.2 (9.3) million, representing 22.9% of net sales.

Cash flow from operations was historically strong at EUR 15.9 (9.8) million. Cash flow from operations strengthened particularly due to efficient working capital management and lower tax payments compared to the previous year.

Profitability was good in January–December – operating profit was EUR 25.4 (25.0) million, representing 23.2% of net sales.



Changes in the USD/EUR exchange rate had a negative impact on net sales and profit in 2025. Operating profit adjusted for non-recurring expenses amounted to EUR 26.5 (26.0) million, representing 24.2 (25.1)% of net sales.

We merge hardware, software and AI

Sales of intraocular pressure measuring devices, or tonometers, were strong in the fourth quarter. In particular, sales of the iCare IC200 tonometer and the iCare HOME2 home tonometer were very strong in the fourth quarter. Sales of the iCare IC100 tonometer were also strong.

In fundus imaging devices, iCare DRSplus in particular, performed very strongly in the fourth quarter. Sales of iCare EIDON AF also grew strongly. During the financial year, we started sales of the new iCare MAIA microperimeter and launched the cloud-based iCare ALTIUS eye health information management solution in the United States. Sales of the iCare MAIA microperimeter performed well in the final quarter of the year, and the device's reception in the market has been extremely promising.

iCare Screening Solutions developed strongly during the year and expanded into several new markets. Net sales generated by software solutions increased significantly and the number of customer sites using iCare ILLUME was already nearly 350 in Europe and measurement volumes more than doubled year-on-year. The core of the iCare Screening Solution, the AI-based iCare RETCAD, was launched earlier this year as part of the iCare ILLUME range and integrated into the iCare brand. The screening solution supports the early detection of eye diseases and strengthens the clinical effectiveness of the screening process. Our distribution network expanded, particularly in EMEA and LATAM, and we won new national screening programs in the Middle East and Central and Northern Europe, among others. In addition, the introduction of iCare ILLUME Connect strengthens our collaboration with opticians, clinics and ophthalmologists and clearly differentiates the iCare Screening Solution from other solutions on the market. The strong development of iCare Screening Solutions also supported the very strong growth in sales of iCare DRSplus imaging devices. The iCare Screening Solution is currently in the marketing authorization process for the US market and clinical trials began in the last quarter of the year. Based on our current assessment, the process-related cost impacts are expected to start materializing in 2026.

Artificial intelligence is becoming a key factor in the transformation of eye care, with the growing need for care and the simultaneous shortage of professionals calling for more efficient solutions. Our AI-powered screening and software solutions facilitate the efficient processing of large patient volumes, support clinical decision-making and help to allocate scarce expert resources to the most demanding cases. Our comprehensive approach that merges hardware, software and AI into seamless end-to-end solutions and leverages our extensive AI partner network, supports the efficiency of care pathways, improves the quality of diagnostics and allows us to build scalable and sustainable business models globally.

We are constantly exploring opportunities to expand our product portfolio through either our own product development or acquisitions that fit our strategy, and we see significant long-term potential in new products, software and the use of AI.

Determined progress in the implementation of the strategy

The implementation of our strategy is progressing with determination in all our focus areas towards the end of our strategy period at the end of 2026. We will organize a Capital Markets Day (CMD) in the fall of 2026. At the event, we will discuss our ongoing strategy update work and focus on the next strategy period 2027–2030.

The competitive advantage of our product portfolio is built on four cornerstones: diagnostic reliability and repeatability of results, patient-centric solutions, seamless connectivity and efficient care pathways. Our software solutions are designed to seamlessly integrate with wider eye care ecosystems.

The availability and delivery capability of our products and solutions remained at a high level throughout the financial year, and we continued to develop quality in all product categories. During the financial year, we invested in the awareness and customer experience of the iCare brand and built new distribution channels outside of eye health for the screening business. In addition, we completed management development programs and introduced a product-oriented operating model (POM) to strengthen customer orientation and agile cooperation. Our competitive product and solution offering lays down a strong foundation for sustainable and profitable growth and our ability to continue to perform strongly as one of the leading companies in our industry.

Sustainability at the core of the strategy

We have continued the determined development of our sustainability efforts. Although we are not required to report in accordance with the Corporate Sustainability Reporting Directive (CSRD) due to the change in EU regulation, the key focus areas of our sustainability work remain unchanged. The double materiality assessment we carried out earlier continues to provide us with a good basis for promoting sustainability work, and its material topics are aligned with our strategy and our previous sustainability program. We will continue to systematically consider sustainability-related risks, opportunities and impacts as part of our business development.

Strong foundation for sustainable and profitable growth

The global need for eye care is increasing as populations age, lifestyle related diseases such as diabetes become more prevalent. At the same time, a declining number of eye care professionals is placing growing pressure on healthcare systems, highlighting the importance of comprehensive and intelligent eye care solutions that enable more efficient screening, prevention and diagnosis while helping reduce the burden on healthcare and improve quality of life worldwide. In parallel, the eye care industry is undergoing consolidation, which is an important structural trend shaping the future development of the sector.

We have demonstrated our ability to grow profitably and sustainably for more than a decade, and our goal is to continue on this path in the future. We are strongly positioned in the industry, supported by strong structural long-term growth drivers and a high entry threshold. We are at the forefront of developing a new generation of solutions that combine technology, artificial intelligence and patient-oriented care. This provides us with significant growth opportunities in the years to come.

Despite the tense geopolitical environment and the ongoing uncertainty associated with it, I have strong confidence in our ability to navigate the changing conditions and continue our profitable growth. Our financial guidance for 2026 reflects our confidence in the strong growth of our business, competitive product and solution offering and the consistent implementation of our strategy.

I would like to extend my warmest thanks for 2025 to all our global employees, owners, partners and other stakeholders. Together, we have built a strong foundation for Revenio's long-term success and ability to create impactful solutions for eye health around the world.

Revenio Group's strategy

The cornerstones of the strategy for 2024–2026 are:

- Improve the quality of clinical diagnostics with targeted product innovations
- Optimize clinical care pathways with connected and predictive solutions
- Enhance customer focus in operations & sales
- Continue to develop People & Culture as a foundational strength
- Continue sustainable and profitable growth

Revenio's key products

Revenio's growth strategy is driven by delivering the highest-quality products and solutions on the market under the iCare brand. The diagnosis and treatment of eye diseases is shifting towards comprehensive patient-oriented and predictive solutions. Revenio is a pioneer in utilizing next-generation technology and artificial intelligence and improving the efficiency of care pathways. In 2025, the company invested 10.5% of net sales in research and development.

Intraocular pressure (IOP) measurement devices, i.e. tonometers

- Tonometers are innovative and easy-to-use devices for measuring intraocular pressure without numbing or air puff, making the measurement accurate and more comfortable for the patient. Tonometers are used for glaucoma screening and monitoring, and they are suitable for clinical, home and veterinary use.

Fundus imaging devices

- Fundus imaging devices provide accurate high-quality images of ocular structures, such as the retina and optic nerve end, and are used to diagnose and monitor fundus diseases, such as glaucoma, age-related macular degeneration, and diabetic retinopathy. The highly automated user-friendly devices utilize advanced technology to produce clear images without pupil dilation.

Fundus perimeters

- Fundusperimeters combine visual field examination, and exceptionally precise fundus imaging in one device for improved diagnostics accuracy. A single examination can determine both the structure and functionality of the fundus. These industry-leading devices are particularly used in the diagnosis and monitoring of glaucoma, as they allow the detection of visual field deficiencies and the evaluation of the effects of treatment.

Microperimeters

- A microperimeter combines retinal imaging and automatic visual field examination in one device, enabling simultaneous viewing of focused retinal sensitivity and monitoring of structural changes. Microperimeters are particularly used for the diagnosis and monitoring of macular degenerative diseases.

Screening solutions

- The iCare Screening Solution integrates detail-rich confocal fundus imaging with iCare DRSplus, cutting-edge AI-powered retinal image analysis with iCare RETCAD, and specialized cloud-based workflow software with iCare ILLUME. This fully automated platform transforms early detection of diabetic retinopathy, age-related macular degeneration (AMD), and glaucoma, streamlines clinical workflows, and enhances the patient care journey. The AI-generated report supports clinical decision-making with speed, consistency, and clarity.

Software solutions

- The comprehensive software solutions support eye health monitoring and diagnostics by providing tools for patient data management, imaging data analysis, and long-term change tracking. They enable the integration and visualization of data collected from various devices, helping eye health professionals make accurate and up-to-date treatment decisions while streamlining care pathways.

Financial review 2025

Net sales, profitability, and profit

October–December 2025

Revenio Group's net sales October 1–December 31, 2025 were EUR 31.2 (30.5) million. Net sales increased by 2.2%. The currency-adjusted increase of net sales was 8.6%. EBITDA was EUR 7.8 (10.3) million, or 24.9% of net sales, down by 24.2%.

The Group's operating profit in October–December was EUR 6.7 (9.1) million, down by 26.9%.

Profit before taxes was EUR 6.8 (9.3) million, down 26.9% year-on-year.

Earnings per share came to EUR 0.208 (0.247). Equity per share came to EUR 4.30 (4.04).

January–December 2025

Revenio Group's net sales January 1–December 31, 2025 was EUR 109.7 (103.5) million. Net sales increased by 6.0%. The currency-adjusted increase of net sales was 9.1%, or 3.2%-points stronger than the reported growth. EBITDA was EUR 29.9 (30.2) million, or 27.3% of net sales, down by 1.1%.

The Group's operating profit in January–December was EUR 25.4 (25.0) million, up by 1.4%. The adjusted operating profit was EUR 26.5 (26.0) million, or 24.2% of net sales, up by 2.3%.

Profit before taxes was EUR 22.8 (24.6) million, down by 7.3% year-on-year.

Earnings per share came to EUR 0.655 (0.695). Equity per share came to EUR 4.30 (4.04).

Balance sheet, financial position and cash flow

The Group's balance sheet total totaled EUR 150.6 (141.3) million on December 31, 2025. The value of goodwill on the balance sheet totaled EUR 62.9 (63.3) million on December 31, 2025.

The Group's equity was EUR 114.7 (107.7) million. The Group's net debt at the end of the period totaled EUR -15.3 (-7.9) million, and net gearing was -13.3 (-7.3)%. The Group's equity ratio was 76.1 (76.2)%. The Group's liquid assets at the end of the financial period on December 31, 2025 totaled EUR 26.2 (20.7) million. Cash flow from operations totaled EUR 30.2 (23.9) million. More efficient working capital management and lower tax payments compared to the previous year particularly influenced the positive development of cash flow from operating activities during the financial period.

Governance

Personnel and management

On December 31, 2025, the members of Revenio Group's Leadership Team were:

- CEO Jouni Toijala
- Vice President, Sales John Floyd
- Vice President, Quality Heli Huopaniemi
- Vice President, Operations Ari Isomäki
- CFO Robin Pulkkinen
- Vice President, R&D Marco Rizzato
- Vice President, Products, Brand and Marketing Erkki Tala
- Vice President Strategy and Business Development Kate Taylor
- Vice President, People & Culture Hanna Vuornos

As reported on December 18, 2025, CFO and member of the Leadership Team, Robin Pulkkinen, has resigned from his position to take on a role outside the company. He will continue working at Revenio during his notice period and will leave the company no later than June 2026.

As announced on January 15, 2026, Kate Taylor, VP, Strategy and Business Development and a member of the Leadership Team, stepped down from her position on January 31, 2026.

Average number of personnel during the financial year

	1-12/2025	1-12/2024
Revenio Group	248	229

At the end of the year, the number of employees was 247 (241).

Board of Directors

Until the Annual General Meeting April 10, 2025, the Company's Board of Directors comprised Arne Boye Nielsen (Chair), Bill Östman (Vice Chair), Riad Sherif, Ann-Christine Sundell, and Pekka Tammela. After the Annual General Meeting 2025, the Company's Board of Directors comprises Arne Boye Nielsen (Chair), Bill Östman (Vice Chair), Heli Lindfors, Anat Loewenstein, Riad Sherif, Ann-Christine Sundell, and Pekka Tammela.

Audit Committee

At its organizing meeting, held after the Annual General Meeting 2025, the Board elected from amongst its members the following members to serve on its Audit Committee: Pekka Tammela (Chair), Heli Lindfors, Arne Boye Nielsen, and Ann-Christine Sundell.

Nomination and Remuneration Committee

At its organizing meeting, held after the Annual General Meeting 2025, the Board elected from amongst its members the following members to serve on its Nomination and Remuneration Committee: Bill Östman (Chair), Riad Sherif and Arne Boye Nielsen.

Auditor

At the Annual General Meeting 2025 Deloitte Oy, Authorized Public Accountants, was re-elected as the Company's auditors, with Mikko Lahtinen, Authorized Public Accountant, as the principal auditor. The Auditor's Fee is to be paid upon as invoiced and approved by the company.

Shares, share capital, and management and employee holdings

On December 31, 2025, Revenio Group Corporation's fully paid-up share capital registered with the Trade Register was EUR 5,314,918.72 and the number of shares totaled 26,681,116.

The Company has one class of shares, and all shares confer the same voting rights and an equal right to dividends and the Company's funds. On December 31, 2025, members of the Board of Directors, the CEO, the Leadership team members, and their related parties held 0.26% of the Company's shares, or 69,990 shares.

The Company did not buy back any of its shares during the financial period. At the end of the financial period, the Company held 77,691 of its own shares.

In late 2015, the employees of Revenio Group working in Finland established a personnel fund, into which any bonuses earned by employees through incentive schemes can be paid. This arrangement is widely used.

The Annual General Meeting of April 10, 2025, decided that approximately 40% of Board members' emolument will be settled in the form of Company shares.

The valid authorizations of the Board of Directors relating to repurchase and issuance of shares are presented in the section on the Annual General Meeting.

Share incentive plans

Revenio Group Corporation's Board of Directors has decided on the three-year performance periods of the performance-based long-term share-based incentive plans for the company's key personnel, that are effect during the financial year 2025, on August 2023 (PSP 2023-2025), March 2024 (PSP 2024-2026) and May 2025 (PSP 2025-2027). Long-term performance-based share plans form part of the Company's remuneration program for key personnel and are aimed at supporting the implementation of the Company's strategy and harmonizing the objective of key personnel and Company shareholders in growing shareholder value. Based on the ended earning period of the share-based incentive plan 2022-2024 (PSP 2022-2024), no shares were transferred to the Company's key personnel participating in the plan.

In addition, if certain conditions are met, the CEO was entitled to a restricted share plan (RSP 2021-2023) under which the CEO would be entitled to receive a total of 3,000 shares in three installments of the Company. This number of shares represents gross earnings, from which the portion required to cover the taxes arising from the share plan and other possible applicable tax-related payments is deducted. The last installment of the share plan, 400 shares, was transferred to the CEO in April 2025.

The Board of Directors decided on March 2024 on the establishment of a new individual restricted share plan structure (RSP 2024-2026) which is intended to be used as a complementary share-based retention plan for the Company's key personnel. The total earnings of the participants in the RSP 2024–2026 share-based incentive plan amounted to 4,180 shares. After taxes and other possible tax-related charges, a total of 2,072 treasury shares were transferred in April 2025 in a directed share issue without payment, relating to the 2024 earning period.

Information on the remuneration schemes currently used in Revenio Group can be found at the Company's website at: www.reveniogroup.fi/en/investors/corporate_governance/remuneration

Flagging notifications

Between January 1–December 31, 2025, Revenio Group Corporation received one notification of any changes in holdings as referred to in Chapter 9, Section 5, of the Securities Markets Act. According to the notification, the total number of Revenio Group Corporation shares owned by William Demant Invest A/S increased to over twenty (20) per cent of the share capital of Revenio Group Corporation.

Management transactions

Transactions in Revenio securities by members of Revenio Group Corporation's management during the financial period have been published as stock exchange releases and can be viewed on the Company website at:

www.reveniogroup.fi/en/releases.

Trading on Nasdaq Helsinki

During the period January 1–December 31, 2025, Revenio Group Corporation's share turnover on the Nasdaq Helsinki exchange totaled EUR 140.2 (135.7) million, representing 5.6 (4.8) million shares or 21.0 (18.1) % of all shares outstanding. The highest transaction price was EUR 31.88 (35.84) and the lowest was EUR 21.35 (23.36). The closing price at the end of the financial period was EUR 22.40 (26.58) and the weighted average price for the financial period was EUR 25.06 (28.08). Revenio Group Corporation's market value stood at EUR 598 (709) million on December 31, 2025.

Summary of trading on Nasdaq Helsinki on January 1–December 31, 2025

January–December 2025	Turnover, number of shares	Value total, EUR	Highest, EUR	Lowest, EUR	Average price, EUR	Latest, EUR
REG1V	5,593,960	140,180,916	31.88	21.35	25.06	22.40
December 31, 2025						
Market value, EUR				597,656,998	709,184,063	
Number of shareholders				21,874	22,902	

Risks and uncertainties

Risks Revenio Group is exposed to include strategic, operational, business cycle, damage, financial, and political risks. In addition, the threat of the global impact of pandemics, climate changes and the risk of cyber threats have increased.

The Group's strategic risks include competition in all sectors, the threat posed by new competing products, and any other actions of the Company's rivals that may affect the competitive situation. Another strategic risk is related to the ability to shift the strategic focus towards integrated and predictive eye care pathways and to succeed in R&D activities and to maintain a competitive product mix. The Group develops new technologies under Icare Finland Oy, Revenio Research Oy, CenterVue Spa and iCare World Australia Pty Ltd, and any failure in the commercialization of individual development projects may result in the depreciation of capitalized development expenses, with an impact on the result. Strategic risks in the Group's segments that require special expertise are also associated with the successful management and development of key human resources and the management of the subcontractor and supplier network. The range and probability of cyber threats has increased. When realized, a cyber threat can affect the continuity of Revenio Group's business, the Group's reputation, or lead to significant sanctions. Risks caused by cyber threats are prepared with technical, administrative and organizational information security development. Climate change is associated, for example, with an increase in extreme weather events, rising global temperatures, and sea level rise. The risks arising from these factors for the Group's business may include, among other things, disruptions in the supply chain.

Corporate acquisitions and the purchase of assets with growth potential related to eye health are part of the Group strategy. The success of these acquisitions has a significant impact on the achievement of growth and profitability targets. Acquisitions may also change the Group's risk profile.

Strategic risks and the need for action are regularly monitored and assessed in connection with day-to-day management, monthly Group reporting, and annual strategy updates.

Operational risks are associated with the retention and development of major customers, the operations of the distribution network, and success in extending the customer base and markets. Operational risks in the eye health sector that the Company specializes in include, in particular, factors related to expansion into new markets, such as various countries' national regulations of marketing authorizations for medical instruments and the related official decisions concerning the health care market. Success in eye health R&D projects launched in accordance with the strategy can also be classified as an operational risk. Furthermore, the global availability challenges related to electronic components may cause operational risks.

The operational risks related to the manufacture, product development, and production control of medical instruments are estimated to be higher than average due to the sector's ambitious requirements concerning quality. Damage-related risks are covered by insurance. Property and business interruption insurance provides protection against risks in these areas. The business activities of the Group are covered by international liability insurance.

Financial risks can be further categorized into credit, interest-rate, liquidity, and foreign exchange risks. The Board assesses financial risks and other financial matters in its monthly meetings, or more frequently, as necessary. If required, the Board provides decisions and guidelines for the management of financial risks including, for example, interest-rate and currency hedging decisions. Liquidity risk can be affected by the availability of external financing, the development of the Group's credit standing, trends in business operations, and changes in the payment behavior of customers. Liquidity risks are monitored by means of cash forecasts, which are drawn up for periods of, at most, 12 months at a time.

Risks related to corporate responsibility are managed as part of the company's risk management process. Corporate responsibility is viewed through economic, environmental and social responsibility.

Revenio Group offers eye health diagnostics solutions under the iCare brand. Reputational damage might have a negative impact on Revenio Group's business. Possible causes for reputational damage include cyber security or compliance challenges or notable delivery or product quality issues. Leakage of sensitive employee or customer data might also lead to reputational damage and notable financial consequences.

Revenio Group products are sold in nearly 100 countries. Economic and political uncertainties, interest and inflation risks and the unstable trade and geopolitical situation may affect the demand for Revenio Group products. Revenio actively monitors political developments in different market areas from a risk management perspective. Developments in national

government policies or changes to relevant legislation may have an impact on the Group's business. The security situation in Europe has changed drastically since the Russia invasion of Ukraine.

Moreover, global pandemics could have direct and indirect effects on Revenio Group's business, including an increased risk of personnel being incapacitated. Government-mandated closures of factories or borders may weaken Revenio Group's operating environment and restrictions on the movement of people could hamper the sales and delivery of Revenio's products.

Corporate responsibility

Revenio is a supplier of comprehensive eye care solutions operating in the international market and a global leader in ophthalmological devices and software solutions. Revenio's business has a positive impact on society by promoting eye health. Revenio takes into account the unique characteristics of the sector's business and operating environment in all its operations concerning responsibility and sustainable development.

In 2025, Revenio updated its sustainability program based on a previously conducted double materiality assessment. The aim is to increase the ambition and concreteness of the sustainability program in the future. The sustainability program encompasses four main themes that are closely tied to the company's core business—promoting eye health and enhancing the quality of life through products and services, such as expanded screening coverage—and also addresses HR responsibility, environmental responsibility, and corporate governance. In 2025, Revenio invested, among other things, in the collection of sustainability data, which helps to identify potential development needs.

In 2025, the EU introduced changes to sustainability legislation, which for Revenio means the selection of the VSME reporting framework for the 2025 report. This supports the sustainability work already initiated based on CSRD and is in line with the recommendations issued. Revenio will also apply the GRI reporting framework in the 2025 report in order to comprehensively serve the diverse information needs of stakeholders. The company is not, due to changes in EU regulation, required to report a sustainability report as defined by the Sustainability Reporting Directive for the financial year 2025.

Revenio complies with laws and regulations, the rules of Nasdaq Helsinki, good corporate governance practices, Revenio's Code of Conduct and agreed operating principles. The purpose of the Group-wide ethical principles is to support decision-making in a global operating environment and to ensure responsible conduct.

With regard to personnel, the most material sustainability topics are employee safety, health and well-being, diversity and inclusion, good leadership and an innovation-supporting corporate culture, as well as competence development and learning. For example, in 2025, Revenio implemented the Vision Shapers training program in cooperation with Aalto EE, offering perspectives on markets, customer-driven innovation, commercial capabilities and personal leadership development. During 2025, Revenio also invested in diversity, and Revenio's Italian HR team received the UNI/PdR 125:2022 gender equality certification granted by the certification body DNV.

Regarding environmental impacts, the most material sustainability topics are the reduction of greenhouse gas emissions and other harmful environmental impacts in own operations and the value chain, as well as the promotion of sustainable and circular product design and the reduction of environmental impacts over the product life cycle. These themes are promoted, among other things, in accordance with the environmentally conscious product design standard IEC 60601-1-9. In 2025, two of our products were certified in accordance with the standard, further strengthening the use of the standard as part of product design. Revenio continued data collection related to emissions calculations in 2025.

Revenio will publish a separate sustainability report for 2025 in March 2026 as part of the annual reporting package. The report will not be assured.

Annual General Meeting and currently valid authorizations of the Board of Directors

Decisions by the Annual General Meeting of Revenio Group Corporation on April 10, 2025

Financial statements, Board and Auditors

The AGM confirmed the company's financial statements for the financial year 1 January – 31 December 2024 and discharged the members of the Board of Directors and the Managing Director from liability.

The AGM decided that seven members be elected to the Board of Directors and elected Arne Boye Nielsen, Heli Lindfors, Anat Loewenstein, Riad Sherif, Ann-Christine Sundell, Pekka Tammela, and Bill Östman as members of the Board of Directors. In the board meeting held after the AGM, the Board of Directors elected Arne Boye Nielsen as Chair of the Board and Bill Östman as Vice Chair of the Board. The Board of Directors also decided the members of Audit Committee and elected Pekka Tammela, Heli Lindfors, Ann-Christine Sundell, and Arne Boye Nielsen. The Board of Directors elected Pekka Tammela as Chair of the Audit Committee. The Board of Directors also decided the members of Nomination and Remuneration Committee and elected Bill Östman, Riad Sherif and Arne Boye Nielsen. The Board of Directors elected Bill Östman as Chair of the Nomination and Remuneration Committee.

The AGM decided that the Chair of the Board be entitled to an annual emolument of EUR 60,000, the possible deputy chair of the Board of Directors be entitled to an annual emolument of EUR 45,000, the Board Members be entitled to an annual emolument of EUR 30,000, the chair of the Audit Committee be entitled to an annual emolument of EUR 20,000, the chair of the Nomination and Remuneration Committee be entitled to an annual emolument of EUR 10,000, and the members of the Board Committees be entitled to an annual emolument of EUR 5,000.

Approximately 40 per cent of the Board members' annual remuneration (gross) will be settled in the form of the company's shares held in its treasury, however not exceeding a maximum of 7,000 shares in total, while approximately 60 per cent will consist of a monetary payment. Tax will be deducted from the monetary payment, calculated on the amount of the entire annual remuneration. The shares will be assigned to the Board members within two weeks of the release of Revenio Group Corporation's interim report for the period of 1 January - 31 March 2025, using the trade volume weighted average price on the day following the release of the interim report as the share value.

The AGM further decided that an attendance allowance of EUR 1,000 for Chair of the Board or Board Committees per Board or Committee meeting and EUR 600 per short teleconference, Board members EUR 600 for Board and Board Committee meetings and EUR 300 for short teleconferences per meeting, yet so that the aforementioned attendance allowance for the Board and Board Committee meetings for Board and Committee chairs who live outside of Finland and travel to Finland for the meeting is EUR 2,000 and the aforementioned attendance allowance for the Board and Board Committee meetings for members is EUR 1,200.

Any travel expenses of the members of the Board or Board Committees will be compensated in accordance with the company's travel expense regulations.

The AGM re-elected Deloitte Ltd, Authorized Public Accountants, as the company's auditors, with Authorized Public Accountant (KHT) Mikko Lahtinen acting as the principal auditor. The same firm was elected as the sustainability auditor. The AGM decided to pay the auditors' fees as invoiced and approved by the company.

Annual profit distribution, dividend distribution and capital repayment

The AGM decided to accept the Board's proposal on profit distribution, according to which a dividend of EUR 0.40 per share will be paid. The dividend will be paid to shareholders who have been registered in the company's shareholder register, maintained by Euroclear Finland Ltd, by the dividend record date on April 15, 2025. The dividend payment date was April 23, 2025.

Authorizing the Board of Directors to decide on the acquisition of own shares

The AGM authorized the Board of Directors to resolve on the acquisition of a maximum of 1,334,055 of the company's own shares in one or more tranches using the company's unrestricted equity.

The company may buy back shares in order to develop its capital structure, finance or implement any corporate acquisitions or other transactions, implement share-based incentive plans, pay board fees or otherwise transfer or cancel them.

The company may buy back shares in public trading on marketplaces whose rules and regulations allow the company to trade in its own shares. In such a case, the company buys back shares through a directed purchase, i.e. in a proportion other than its shareholders' holdings of company shares, with the consideration paid for the shares based on their publicly quoted market price so that the minimum price of the purchased shares equals the lowest market price quoted in public trading during the authorization period and their maximum price equals the highest market price quoted in public trading during that period.

The authorization is effective until the end of the Annual General Meeting held in 2026, yet no further than until June 30, 2026. This authorization shall supersede the authorization granted at the Annual General Meeting of April 4, 2024.

Authorizing the Board of Directors to decide on a share issue and on granting stock options and other special rights entitling to shares

The AGM decided to authorize the Board of Directors to decide on issuing a maximum of 2,668,111 shares in a share issue or by granting special rights (including stock options) entitling holders to shares as referred to in Chapter 10 Section 1 of the Companies Act, in one or several tranches.

This authorization is to be used to finance and implement any prospective corporate acquisitions or other transactions, to implement the company's share-based incentive plans, or for other purposes determined by the Board.

The authorization grants the Board the right to decide on all terms and conditions governing the share issue and the granting of said special rights, including on the recipients of the shares or special rights and the amount of payable consideration. The authorization also includes the right to issue shares by deviating from the shareholders' pre-emptive rights, i.e. by issuing them in a directed manner. The authorization of the Board covers both the issue of new shares and the transfer of any shares that may be held by the company.

The authorization is effective until the end of the Annual General Meeting held in 2026, yet no further than until June 30, 2026. This authorization shall supersede the issue authorization granted at the Annual General Meeting of April 4, 2024.

Proposal by the Board of Directors for distribution of profit

The Group's profit for the financial year 2025 was EUR 17,412 thousand and the parent Company's profit was EUR 13,419,416,45. The parent Company's distributable assets on December 31, 2025, amounted to EUR 102,111,040.26. The Board will propose to the Annual General Meeting of April 15, 2026, that the General Meeting authorizes the Board to decide, at its discretion, on the payment of a possible dividend of up to EUR 0.44 per share, a maximum total of EUR 11,739,691.04, by December 31, 2026, with the remaining distributable assets to be added to equity. The dividend may be paid in one or more instalments. Based on the authorization granted to the Board, the Board shall determine the record date and the payment date when deciding on the payment of the dividend. The remaining distributable assets are to be added to equity. As consolidation in the industry continues, it is important that the Company maintains its financial flexibility. The Board of Directors finds that the proposed distribution of profit does not endanger the liquidity of the parent Company or the Group.

Events after the financial period

After the financial period, on January 15, 2026, Revenio announced changes in its Leadership team from February 1, 2026. Leadership team member Dr. Kate Taylor (Vice President, Strategy and Business Development), will step down from her position by January 31, 2026. The responsibilities of Vice President, Strategy and Business Development will be shared by the CEO Jouni Toijala and the Leadership Team.

Major shareholders on December 31, 2025*

		No. of shares	%
1	William Demant Invest A/S	6,532,461	24.48%
2	SEB Funds	1,220,695	4.58%
3	Vanguard	884,038	3.31%
4	Ilmarinen Mutual Pension Insurance Company	803,118	3.01%
5	Varma Mutual Pension Insurance Company	446,166	1.67%
6	Handelsbanken Funds	444,172	1.66%
7	BlackRock	409,658	1.54%
8	Elo Mutual Pension Insurance Company	406,000	1.52%
9	Evli Fund Management	376,073	1.41%
10	Case Kapitalförvaltning	363,754	1.36%

* Monitor by Modular Finance AB. Compiled and processed ownership data from various public sources, including Euroclear Finland and Morningstar, and from direct shareholder disclosures. While all efforts have been made to secure as updated and complete information as possible, neither Modular Finance nor Revenio Group can guarantee the completeness or accuracy of the data.

Financial statements January 1–December 31, 2025, tables

Accounting policies applied in the preparation of the financial statements

This financial statement release has been drawn up in accordance with IAS 34 Interim Financial Reporting and the same principles as the financial statements for 2024, except for the following amendments to the existing standards, which the Group has applied as of January 1, 2025:

Amendments made to IAS 21.

In the management's estimate, the adoption of the above-mentioned standards does not have a material impact on the Group's financial statements. The figures of the financial statement release are unaudited.

Consolidated comprehensive income statement

MEUR	10-12/2025	10-12/2024	1-12/2025	1-12/2024
NET SALES	31.2	30.5	109.7	103.5
Other operating income	0.2	0.2	0.2	0.3
Materials and services	-10.1	-8.8	-31.9	-30.6
Employee benefits	-7.1	-6.5	-26.4	-23.1
Depreciation, amortization, and impairment	-1.1	-1.1	-4.5	-5.2
Other operating expenses	-6.4	-5.2	-21.7	-20.0
NET PROFIT/LOSS	6.7	9.1	25.4	25.0
Financial income and expenses (net)	0.1	0.1	-2.6	-0.4
PROFIT BEFORE TAXES	6.8	9.3	22.8	24.6
Income taxes	-1.2	-2.7	-5.4	-6.1
NET PROFIT	5.5	6.6	17.4	18.5
Other comprehensive income items	0.2	-0.2	-0.2	-1.0
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	5.7	6.4	17.3	17.5
Earnings per share, EUR	0.208	0.247	0.655	0.695

Consolidated balance sheet

MEUR	31.12.2025	31.12.2024
ASSETS		
NON-CURRENT ASSETS		
Goodwill	62.9	63.3
Intangible assets	23.3	22.0
Tangible assets	2.1	2.4
Right-of-use assets	5.0	2.6
Other non-current financial assets	0.5	0.4
Other receivables	0.3	0.2
Deferred tax assets	3.7	3.4
TOTAL NON-CURRENT ASSETS	97.8	94.3
CURRENT ASSETS		
Inventories	10.8	10.1
Trade and other receivables	15.8	16.2
Cash and cash equivalents	26.2	20.7
TOTAL CURRENT ASSETS	52.8	47.0
TOTAL ASSETS	150.6	141.3
SHAREHOLDERS' EQUITY AND LIABILITIES		
SHAREHOLDERS' EQUITY		
Share capital	5.3	5.3
Fair value reserve	-0.4	-0.4
Reserve for invested unrestricted capital	52.0	52.1
Other reserves	0.3	0.3
Retained earnings/loss	59.4	52.2
Translation difference	-0.3	-0.1
Own shares held by the company	-1.6	-1.7
TOTAL SHAREHOLDERS' EQUITY	114.7	107.7
LIABILITIES		
NON-CURRENT LIABILITIES		
Deferred tax liabilities	3.5	3.6
Financial liabilities	3.0	6.9
Lease liabilities	3.6	1.5
TOTAL LONG-TERM LIABILITIES	10.2	12.0
CURRENT LIABILITIES		
Trade and other payables	19.3	15.5
Provisions	0.8	0.6
Financial liabilities	4.2	4.2
Lease liabilities	1.5	1.3
TOTAL CURRENT LIABILITIES	25.8	21.6
TOTAL LIABILITIES	35.9	33.6
TOTAL SHAREHOLDERS' EQUITY		
AND TOTAL LIABILITIES	150.6	141.3

Consolidated statement of changes in equity

MEUR	Share capital	Reserve for invested unrestricted equity	Other reserves	Retained earnings	Translation difference	Own shares	Total equity
Balance 1 Jan 2025	5.3	52.1	-0.1	52.2	-0.1	-1.7	107.7
Dividend distribution	0.0	0.0	0.0	-10.6	0.0	0.0	-10.6
Disposal and purchase of own shares	0.0	-0.1	0.0	0.0	0.0	0.1	0.0
Other direct entries to retained earnings	0.0	0.0	0.0	0.4	0.0	0.0	0.4
Result for the financial year	0.0	0.0	0.0	17.4	0.0	0.0	17.4
Other comprehensive income	0.0	0.0	0.0	0.0	-0.2	0.0	-0.2
Balance 31 December 2025	5.3	52.0	-0.1	59.4	-0.3	-1.6	114.7
MEUR	Share capital	Reserve for invested unrestricted equity	Other reserves	Retained earnings	Translation difference	Own shares	Total equity
Balance 1 Jan 2024	5.3	52.2	0.6	43.5	0.0	-1.7	99.9
Dividend distribution	0.0	0.0	0.0	-10.1	0.0	0.0	-10.1
Disposal and purchase of own shares	0.0	-0.1	0.0	0.0	0.0	0.1	0.0
Other direct entries to retained earnings	0.0	0.0	0.0	0.4	0.0	0.0	0.4
Result for the financial year	0.0	0.0	0.0	18.5	0.0	0.0	18.5
Other comprehensive income	0.0	0.0	-0.8	-0.1	-0.1	0.0	-1.0
Balance 31 December 2024	5.3	52.1	-0.1	52.2	-0.1	-1.7	107.7

Consolidated cash flow statement

MEUR	10-12/2025	10-12/2024	1-12/2025	1-12/2024
CASH FLOW FROM OPERATIONS				
Profit for the period	5.5	6.6	17.4	18.5
Adjustments:				
Depreciation, amortization, and impairment	1.1	1.1	4.5	5.2
Other non-cash items	0.3	0.8	1.3	1.0
Interest and other financial expenses	0.0	0.0	3.1	0.7
Interest income and other financial income	-0.1	-0.1	-0.6	-0.2
Taxes	1.2	2.7	5.4	6.1
Other adjustments	0.0	0.0	-0.1	-0.1
Change in working capital:				
Changes in sales and other receivables	0.2	-3.5	1.3	-2.4
Changes in current assets	-0.7	0.9	-0.7	0.4
Changes in trade and other payables	7.5	3.8	3.5	2.4
Change in working capital, total	7.0	1.2	4.1	0.4
Interest paid	-0.1	-0.2	-0.4	-0.8
Interest received	0.1	0.2	0.1	0.3
Taxes paid	0.8	-2.6	-4.6	-7.1
NET CASH FLOW FROM OPERATING ACTIVITIES	15.9	9.8	30.2	23.9
CASH FLOW FROM INVESTING ACTIVITIES				
Acquisitions of subsidiaries less cash and cash equivalents at acquisition time	0.0	-0.1	0.0	-4.7
Purchase of tangible assets	-0.5	-0.4	-1.1	-1.2
Purchase of intangible assets	-1.1	-1.0	-3.1	-3.0
Investments in other receivables	-1.1	0.0	-1.1	0.0
NET CASH FLOW FROM INVESTING ACTIVITIES	-2.6	-1.4	-5.2	-8.8
CASH FLOW FROM FINANCING ACTIVITIES				
Repayments of loans	-1.1	-1.0	-4.2	-4.6
Dividends paid	0.0	0.0	-10.6	-10.1
Payments of lease agreement liabilities	-0.4	-0.4	-1.7	-1.4
NET CASH FLOW FROM FINANCING ACTIVITIES	-1.4	-1.4	-16.6	-16.1
Net change in cash and credit accounts	11.8	6.9	8.4	-1.1
Cash and cash equivalents at beginning of period	14.4	13.5	20.7	21.5
Effect of exchange rates	0.1	0.3	-2.9	0.2
Cash and cash equivalents at end of period	26.2	20.7	26.2	20.7

Key figures

MEUR	10-12/2025	10-12/2024	1-12/2025	1-12/2024
Net sales	31.2	30.5	109.7	103.5
EBITDA	7.8	10.3	29.9	30.2
EBITDA-%	24.9	33.6	27.3	29.2
Operating profit	6.7	9.1	25.4	25.0
Operating profit-%	21.4	29.9	23.2	24.2
Pre-tax profit	6.8	9.3	22.8	24.6
Pre-tax profit-%	21.7	30.4	20.8	23.8
Net profit	5.5	6.6	17.4	18.5
Net profit-%	17.8	21.5	15.9	17.9
Gross capital expenditure	1.7	1.4	4.3	4.3
Gross capital expenditure-%	5.6	4.7	3.9	4.2
R&D costs	3.9	2.5	11.6	10.4
R&D costs-% from net sales	12.4	8.3	10.5	10.0
Gearing-%	-13.3	-7.3	-13.3	-7.3
Equity ratio-%	76.1	76.2	76.1	76.2
Return on investment-% (ROI)	6.6	8.4	20.8	22.1
Return on equity-% (ROE)	5.0	6.3	15.7	17.8
Earnings per share, EUR	0.208	0.247	0.655	0.695
Equity per share, EUR	4.30	4.04	4.30	4.04
Average no. of employees	249	239	248	229
Cash flow from operating activities	15.9	9.8	30.2	23.9
Cash flow from investing activities	-2.6	-1.4	-5.2	-8.8
Net cash used in financing activities	-1.4	-1.4	-16.6	-16.1
Total cash flow	11.8	6.9	8.4	-1.1

Alternative key figures used in financial reporting

Revenio Group Corporation has adopted the guidelines of the European Securities and Market Authority (ESMA) on Alternative Performance Measures. In addition to the IFRS-based key figures, the Company will publish certain other generally used key figures that may, as a rule, be derived from the income statement and balance sheet. The calculation of these figures is presented below. According to the Company's view, these key figures supplement the income statement and balance sheet, providing a better picture of the company's financial performance and position.

Revenio Group's reported net sales are strongly affected by fluctuations in the exchange rate between the euro and the US dollar. As an alternative key figure, the Company also presents net sales with the exchange rate effect eliminated.

Currency-adjusted net sales (EUR thousand)	1-12/2025
Reported net sales	109,677
Effect of exchange rates on net sales	-2,386
Net sales adjusted by the effect of exchange rates	112,063
Growth in net sales, adjusted by the effect of exchange rates	9.1%
Reported net sales growth	6.0%
Difference, % points	3.2%

As an alternative key figure, the Company also presents operating profit (EBITDA) and operating profit adjusted by non-recurring costs.

Operating profit, EBITDA (EUR thousand)	1-12/2025	1-12/2024
Operating profit, EBIT	25,411	25,050
Depreciation, amortization, and impairment	4,490	5,189
EBITDA	29,901	30,239

Operating profit adjusted by non-recurring costs (EUR thousand)	1-12/2025	1-12/2024
Operating profit, EBIT	25,411	25,050
One-time write downs	0	731
Costs from one-time projects	1,137	178
Adjusted operating profit, EBIT	26,548	25,958

Formulas

EBITDA	$\text{EBITDA} = \text{Operating profit} + \text{amortization} + \text{impairment}$
Gross margin	$\text{Sales revenue} - \text{variable costs}$
Earnings per share	$\frac{\text{Net profit for the period (attributable to the parent company's shareholders)}}{\text{Average number of shares during the period} - \text{own shares purchased}}$
Equity ratio, %	$\frac{\text{Shareholders' equity} + \text{non-controlling interest}}{\text{Balance sheet total} - \text{advance payments received}} \times 100$
Net gearing, %	$\frac{\text{Interest-bearing debt} - \text{cash and cash equivalents}}{\text{Total equity}} \times 100$
Return on equity (ROE), %	$\frac{\text{Profit for the period}}{\text{Shareholders' equity} + \text{non-controlling interest}} \times 100$
Return on investment (ROI), %	$\frac{\text{Profit before taxes} + \text{interest and other financial expenses}}{\text{Balance sheet total} - \text{non-interest-bearing debt}} \times 100$
Equity per share	$\frac{\text{Equity attributable to shareholders}}{\text{Number of shares at the end of the period}}$

Financial reporting in 2026

Annual reporting package 2025, including the Report by the Board of Directors and Financial Statements, will be published during week 13 in 2026 on the company website.

The interim report Q1/2026 will be published on Tuesday, April 28, 2026. The half-year report H1/2026 will be published on Thursday, August 6, 2026, and the interim report Q3/2026 will be published on Thursday, October 29, 2026.

Audiocast and teleconference

Revenio will hold a live audiocast and teleconference call for analysts, investors, and media in English at 3.00 p.m. (EET) on February 11, 2026. CEO Jouni Toijala and CFO Robin Pulkkinen will present the Financial statement release.

The audiocast can be watched live at: revenio.events.inderes.com/q4-2025

To ask questions, please join the teleconference by registering using the following link:
events.inderes.com/revenio/q4-2025/dial-in

Phone numbers and the conference ID to access the conference will be provided after registration. To ask a question, please press #5 on your telephone keypad to enter the queue.

A recording of the audiocast will be published on www.reveniogroup.fi/en after the event.

Disclaimer

This report contains certain statements that are estimates based on the management's best knowledge at the time they were made. For this reason, they involve a certain amount of inherent risk and uncertainty. The estimates may change in the event of significant changes in the general economic conditions.

Revenio Group Corporation
Board of Directors

For further information, please contact

President and CEO Jouni Toijala: +358 50 484 0085
jouni.toijala@revenio.fi

CFO Robin Pulkkinen, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi

Distribution

Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media
www.reveniogroup.fi/en

Revenio Group in brief

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand.

In 2025, the Group's net sales totaled EUR 109.7 million, with an operating profit of EUR 25.4 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.